• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Icon launches risk-based monitoring service

Icon launches risk-based monitoring service

August 26, 2013
CenterWatch Staff

Global CRO Icon has launched ICONIK Monitoring, the first in a series of new services that will leverage its ICONIK technology platform.

ICONIK Monitoring enables the targeted use of monitoring resources by using scientific analysis of real-time data, together with CRA site knowledge, to direct central and on-site monitoring activities based on need. It uses event, data volume and risk-based triggers to ensure effective use of monitoring resources. It is designed to meet regulatory and quality requirements for GCP and is consistent with the guidance documents published by the FDA and EMA on risk-based monitoring, and with the TransCelerate Risk Based Monitoring Methodology.

Icon continuously refines the metrics selected for surveillance using ICONIK monitoring and the algorithms used to calculate those metrics. These settings and the pre-programmed methodologies for combing databases and comparing data points can be adapted to suit the study protocol and therapeutic area.

“ICONIK Monitoring enables us to rapidly identify and resolve site-related issues and achieve a higher level of process and data consistency across sites,” said Dr. Nuala Murphy, executive vice president, global clinical and data operations, Icon Clinical Research.  “By ensuring more effective use of site visits, ICONIK Monitoring can also reduce study costs and in some large studies these savings can be as high as 15% to 25% of the overall cost of the study.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing